Novavax Reports First Quarter 2024 Financial Results and Operational Highlights

Announces co-exclusive licensing agreement with Sanofi to co-commercialize COVID-19 vaccine, develop novel COVID-19-Influenza combination vaccines and develop multiple new vaccines utilizing Novavax's Matrix-MTM adjuvant This agreement represents a potential multi-billion dollar revenue opportunity for Novavax including: $500 million upfront payment Approximately$70 million equity investment in Novavax Up to $700 million in COVID-19 and combination product near-term milestones, plus ongoing tiered royal ...